Crinetics Pharmaceuticals
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Crinetics Pharmaceuticals's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 15% to $4,013,000. Profit margin reached -5346%. Total operating expenses were $226,621,000.
Profit Margin
| 2016 | 589K | -6.01M | -1021.9% |
|---|---|---|---|
| 2017 | 2.04M | -9.15M | -447.78% |
| 2018 | 2.42M | -27.11M | -1116.76% |
| 2019 | 1.19M | -49.53M | -4152.14% |
| 2020 | 71K | -72.86M | -102625.35% |
| 2021 | 1.07M | -106.71M | -9899.72% |
| 2022 | 4.73M | -159.95M | -3376.69% |
| 2023 | 4.01M | -214.52M | -5345.85% |
CRNX Income Statement (2016 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||
Revenue | 4.01M | 4.73M | 1.07M | 71K | 1.19M | 2.42M | 2.04M | 589K |
Cost of revenue | 0 | 1.38M | 1.26M | 56.99M | 1.11M | 0 | 9.23M | 0 |
Gross profit | 4.01M | 3.34M | -184K | -56.92M | 80K | 2.42M | -7.18M | 589K |
Operating exp. | ||||||||
Research and development | 168.52M | 130.22M | 84.25M | 56.99M | 41.50M | 24.47M | 9.23M | 5.1M |
Selling and marketing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 226.62M | 172.61M | 108.78M | 74.95M | 53.83M | 28.71M | 9.12M | 6.04M |
Operating income | -222.60M | -167.88M | -107.70M | -74.95M | -53.83M | -28.71M | -9.12M | -6.04M |
Other income (expenses), net | 8.07M | 3.96M | 61K | 1.14M | 3.41M | 1.59M | -30K | -1K |
Income before tax | -214.52M | -163.91M | -107.64M | -73.81M | -50.42M | -27.11M | -9.15M | -6.01M |
Income tax expense | 0 | -3.96M | -922K | -948K | -887K | 1.59M | -40K | 10K |
Net income | -214.52M | -159.95M | -106.71M | -72.86M | -49.53M | -27.11M | -9.15M | -6.01M |
Earnings per share | ||||||||
Basic EPS | -3.69 | -3.08 | -2.78 | -2.39 | -2.05 | -2.23 | -0.66 | -0.43 |
Diluted EPS | -3.69 | -3.08 | -2.78 | -2.39 | -2.05 | -2.23 | -0.66 | -0.43 |
| Data source | Data source | Data source | Data source | Data source |